Select publications

Jones SE. A new estrogen receptor antagonist An overview of available data. Breast Cancer Res Treat 2002;75(Suppl 1):19-21;33-5. Abstract

Mauriac L et al. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials. Eur J Cancer 2003;39(9):1228-33. Abstract

Morris C, Wakeling A. Fulvestrant ('Faslodex') A new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer 2002;9(4):267-76. Abstract

Osborne CK et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002;20(16):3386-95. Abstract

Parker LM. Sequencing of hormonal therapy in postmenopausal women with metastatic breast cancer. Clin Ther 2002;24(Suppl C):43-57. Abstract

Parker LM et al. Greater duration of response in patients receiving fulvestrant ('Faslodex') compared with those receiving anastrozole ('Arimidex'). Proc ASCO 2002; Abstract 160.

Perey L et al. Fulvestrant ('Faslodex') as a hormonal treatment in postmenopausal patients with advanced breast cancer progressing after treatment with tamoxifen and non-steroidal aromatase inhibitors: An ongoing Phase II SAKKtrial. San Antonio Breast Cancer Symposium 2002;Poster 249. No abstract available

Robertson JF. Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer. Clin Ther 2002;24(Suppl A):A17-30. Abstract

Robertson JF, Harrison MP. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol 2003;52(4):346-8. Abstract